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Abstract 
The spread of high-level pyrimethamine resistance in Africa threatens to curtail the 
therapeutic lifetime of antifolate antimalarials. We have studied the possible 
evolutionary pathways in the evolution of pyrimethamine resistance using an 
approach in which all possible mutational intermediates were created by site-
directed mutagenesis and assayed for their level of drug resistance. The coding 
sequence for dihydrofolate reductase (DHFR) from the malaria parasite Plasmodium 
falciparum was mutagenized, and tests carried out in Escherichia coli under 
conditions in which the endogenous bacterial enzyme was selectively inhibited. We 
studied four key amino acid replacements implicated in pyrimethamine resistance, 
namely N51I, C59R, S108N, and I164L. Using empirical estimates of the mutational 
spectrum in P. falciparum, and probabilities of fixation based on the relative levels of 
resistance, the predicted favored pathways of drug resistance are consistent with 
previous kinetic studies as well as DHFR polymorphisms observed in natural 
populations. We find that three pathways account for nearly 90% of the simulated 
realizations of the evolution of pyrimethamine resistance. The most frequent 
pathway (S108N and then C59R, followed by N51I and then I164L) accounts for more 
than half of the simulated realizations. Our results also suggest an explanation of 
why I164L is detected in Southeast Asia and South America, but not so far at 
significant frequencies in Africa. Lozovsky et al. Page 3 
 
\body 
Understanding the molecular evolution of drug resistance has potential clinical 
implications for the development of therapeutic protocols to forestall resistance, the 
rational design of modified drugs that target resistant proteins, and the deployment of 
more effective drugs less likely to promote resistance. More generally, understanding 
the acquisition of drug resistance can reveal broader features of the multidimensional 
fitness landscape that organisms traverse as they evolve, and the constraints that this 
landscape imposes on their evolution. 
  The malaria parasite offers promising opportunities for such studies, as the 
useful therapeutic lifetime of most first-line malaria drugs has been compromised by 
the evolution of parasite resistance. Notable examples include chloroquine (1), 
atovaquone (2), and pyrimethamine (3, 4). Both chloroquine resistance and 
pyrimethamine resistance are associated with multiple amino acid replacements in the 
target protein (5, 6). Mutations in other parasite genes may also contribute 
quantitatively to increase the resistance phenotype or enhance parasite fitness (7-9). 
  In this study we focus on the evolution of resistance to pyrimethamine, a drug 
that competitively inhibits the parasite enzyme dihydrofolate reductase [DHFR, E.C. 
1.5.1.3]. DHFR is part of a bifunctional enzyme needed for the synthesis of 
tetrahydrofolate, an essential precursor of purines and several amino acids (10, 11). 
While pyrimethamine and other antifolates are currently the first-line treatment of 
malaria in many parts of Africa (12-14), high-level resistance has been reported 
elsewhere (4, 13, 15). The genetic basis of pyrimethamine resistance in P. falciparum is 
associated with a small number of amino acid replacements in the parasite DHFR (3, 4, 
16-18). Each of these replacements has been observed in clinical isolates of resistant 
strains (14, 19-21). Resistant mutants in DHFR are generally associated with some Lozovsky et al. Page 4 
combination of four amino acid changes—in particular, Asn51 to Ile (N51I), Cys59 to 
Arg (C59R), Ser108 to Asn (S108N), and Ile164 to Leu (I164L). These four replacements 
affect the enzyme-binding pocket and reduce the binding affinity for pyrimethamine 
(22). Some of the mutants also compromise the endogenous DHFR enzymatic efficiency 
(6). Resistant mutants of DHFR appear to have arisen in Southeast Asia and then spread 
to Africa (23). No other point mutations in the DHFR gene are commonly associated 
with drug resistance, although a few rare variants associated with heightened resistance 
have been reported (24).   
In view of the continuing clinical importance of antifolates in treating malaria in 
Africa, the pathways by which resistance may have evolved are of immediate interest. 
While protein evolution proceeds largely via the sequential replacement of individual 
amino acids, there are processes, trade-offs, and interactions that can constrain the 
temporal order in which these replacements occur. Factors that may constrain the 
realized evolutionary pathways or trajectories include: 
• Mutation bias, which in the malaria parasite is a strong bias toward AT, and 
therefore favors AT-rich codons over others (25); 
• Adaptive conflict, because some amino acid replacements that increase drug 
resistance may also impair the endogenous function of the protein (6). 
• Epistasis resulting from non-additive interactions between mutant sites in the 
same gene, because the effect of any amino acid replacement may depend on the 
sequence context in which it occurs (26). 
• Epistasis resulting from non-additive interactions between mutations in 
different genes, because the evolution of any enzyme in a metabolic pathway alters the 
selection pressures acting on other enzymes in the same metabolic pathway or others 
(27). Lozovsky et al. Page 5 
In principle, the evolutionary pathways of drug resistance could be 
reconstructed by selection for resistance in cultured isolates. Experimental systems in 
which the parasite enzyme is studied in either transgenic bacteria (17) or yeast (28) have 
been developed, and both approaches have been successful in identifying amino acid 
sites important in clinical drug resistance as well as novel resistance sites not observed 
in nature. Kinetic studies of putative intermediates found as polymorphisms in natural 
populations have also proven informative in inferring the stepwise evolution of drug 
resistance (6). The results suggest three likely pathways by which pyrimethamine 
resistance may have evolved (6). 
  In the present experiments, we adopted a third approach, which is to genetically 
engineer and analyze the phenotypes of all possible combinations of the amino acid 
replacements implicated in drug resistance. In previous experiments carried out to 
examine possible pathways for the evolution of various functions in a number of 
proteins (29-32), epistasis among the mutant sites substantially reduced the number of 
selectively accessible mutational pathways. Mutational bias and adaptive conflicts were 
not explicitly addressed. These limitations were addressed in the present analysis in 
two ways. First, we assumed the mutational biases implied by changes in genome 
sequence in the evolutionary lineage of P. falciparum. Second, in the experimental 
studies, we used the transgenic bacterial system in which each bacterial strain contained 
an alternatively mutated DHFR coding sequence from P. falciparum. The endogenous 
bacterial enzyme was inhibited with an antifolate to which the parasite enzyme is 
naturally resistant. The transgenic mutant genotypes therefore have an adaptive conflict 
that trades resistance to inhibition by pyrimethamine against efficient conversion of 
dihydrofolate into tetrahydofolate, which impinges on growth rate in the absence of 
pyrimethamine. The results suggest that this trade-off may provide a hypothesis to help Lozovsky et al. Page 6 
explain why the quadruple DHFR mutant so widespread in Southeast Asia has not yet 
spread in Africa.  
  Overall, our results confirm but also extend previous hypotheses on the 
evolutionary pathways of pyrimethamine resistance. Our inferences take earlier results 
a step farther in being able to estimate a probability for the realization of each possible 
pathway of the evolution of pyrimethamine resistance. The most frequent pathway 
accounts for more than half of all realizations in simulated evolutionary replays, and 
the top three account for 87.5% percent of the realizations. Our results are discussed in 
the contexts of clinical resistance of P. falciparum to antifolates, protein folding and 
function, and more generally protein evolution. 
 
Results 
 
By means of site-directed mutagenesis of a bacterial plasmid containing the coding 
sequence of P. falciparum DHFR, we created all 16 possible combinations of the mutants 
Asn51Ile (N51I), Cys59Arg (C59R), Ser108Asn (S108N), and Ile164Leu (I164L). The 
sequences of the mutagenized DHFR genes were confirmed by direct sequencing. 
 
Drug-Resistance Assays 
Assays for pyrimethamine resistance were carried out by means of a bacterial 
complementation system (17). In this system, the endogenous bacterial enzyme was 
chemically inhibited by 5 µM trimethoprim, a concentration sufficient to prevent 
bacterial growth. The P. falcarium DHFR enzyme is insensitive to trimethoprim, and so 
can complement the inhibited bacterial enzyme. The bacterial system therefore requires 
that the DHFR enzyme activity be sufficient to allow the cells to grow, which in the 
presence of pyrimethamine represents an adaptive conflict between drug resistance and 
catalytic activity. Lozovsky et al. Page 7 
  The level of pyrimethamine resistance was estimated as the concentration of 
drug that inhibited cell growth by 50 percent, a metric referred to as inhibitory 
concentration 50 and symbolized IC50. Bacterial strains carrying each of the DHFR 
alleles were assayed across a range of pyrimethamine concentrations, and growth rate 
as a function of pyrimethamine concentration was estimated by polynomial regression. 
To determine the empirical distribution of IC50 estimates, the IC50 value for each of the 
16 DHFR alleles was estimated in 4–8 independent biological replicates, each with 4 
technical replicates.  
  The results are shown in Fig. 1 in the form of a bar graph, and in tabular form in 
the Table S1. The DHFR alleles indicated along the horizontal axis are given in the form 
of a vector of 0's and 1's that correspond left-to-right to residues 51, 59, 108, and 164. 
Each 0 indicates a nonmutant codon and each 1 a mutant codon. The symbol 0000 
therefore represents the nonmutant sequence NCSI whereas 1111 represents the 
quadruple mutant IRNL. The error bars are equal to the standard deviation of each of 
the distributions of estimated IC50 values. Larger values of IC50 can be estimated with 
greater precision than smaller ones. The coefficient of variation is about 30% of the 
mean for IC50 values < 10 µg/ml, and about 5% of the mean for values > 10 µg/ml. 
  Fig. 1 shows that two of the four possible single mutants (1000 and 0001) are 
about equally sensitive to pyrimethamine as the nonmutant allele 0000. The first step in 
the evolutionary pathway toward pyrimethamine resistance is therefore likely to be 
either 0010 or 0100. Beyond that, the favored evolutionary pathways are not clear from 
inspection, although the quadruple mutant is obviously much more resistant than any 
of the triple mutants. 
  While the average IC50 of the single, double, and triple mutants steadily 
increases from 3.06 µg/ml to 49.9 µg/ml to 137.6 µg/ml, respectively, the complexity of 
the drug-resistance landscape is evident from Fig. 1. Compare the values among the Lozovsky et al. Page 8 
double mutants, for example, whose IC50s range from 0 to almost 150 µg/ml. A notable 
example of epistatic interaction among the mutant sites is allele 0011, which is 
extremely sensitive to pyrimethamine, whereas its single-mutant constituents 0010 and 
0001 have IC50 values of 9.56 µg/ml and 0.29 µg/ml, respectively. The growth of strains 
containing 0011 is impaired even in the absence of pyrimethamine. In particular, the 
growth rate of 0011 relative to that of 0000 in the absence of the drug is 0.169 ± 0.002, 
whereas the relative growth rates of 0010 and 0001 are 1.103 ± 0.009 and 0.968  ± 0.004, 
respectively. In other words, the combination of two mutants, each with a virtually 
normal growth rate in the absence of drug, results in a double mutant whose growth is 
severely impaired. The inability of 0011 to grow in pyrimethamine is a good illustration 
of the adaptive conflict between resistance to inhibition and residual enzyme activity. 
  The IC50 values in Fig. 1 are in good agreement with another widely used metric 
of drug resistance, the minimal inhibitory concentration (MIC), which refers to the 
smallest concentration of the drug that can completely inhibit growth (Table S1). 
Although the solubility of pyrimethamine limits the discrimination among the MIC 
values of the most highly resistant alleles, the concordance between the estimated IC50 
and MIC values is very high. Because it is the relative ranking of the DHFR alleles that 
matters most in inferring the possible evolutionary pathways, this is the relevant 
comparison, and the linear association exhibits r
2 = 0.81. The linear association between 
the raw resistance scores of IC50 and MIC has r
2 = 0.68, but as noted this comparison is 
less relevant. The close correspondence between the rank ordering of alleles according 
to IC50 and MIC seems to exclude the possibility that the analysis of the evolutionary 
pathways to pyrimethamine resistance is unduly influenced by the choice of resistance 
assay. 
 
Evolutionary Model Lozovsky et al. Page 9 
To analyze the data in Fig. 1, we employed an evolutionary model in which selection 
acts to increase pyrimethamine resistance. Selection pressure is assumed to be strong 
relative to mutation pressure, which implies that the time to fixation or loss of a newly 
arising mutation is much shorter that the time between the occurrence of new 
mutations. We also assume that the population size is sufficiently large that random 
genetic drift has a negligible effect on the probability of fixation. In this model, the 
selectively driven fixation or loss of each newly arising mutant takes place before the 
next mutation occurs, and so an evolutionary trajectory consists of a succession of new 
mutant alleles becoming fixed, each of which increases the level of drug resistance (30). 
In the mutational process, we allow all possible single-mutant neighbors to occur, 
including reversions of previously fixed mutations (33). Selection was based only on the 
relative values of IC50, and differences in growth rate in the absence of drug were not 
explicitly taken into account. The rationale is that IC50 values differ among alleles by a 
factor of more than 1000, whereas for most alleles the growth rates in the absence of 
drug differ by no more than a factor of 2 (Table S2). The presence of any significant 
drug pressure therefore swamps selection attributable to intrinsic differences in growth 
rate; however, as discussed later, the case of the quadruple mutant is especially 
interesting in the light of potential compensatory mutations. 
  The evolutionary model also incorporated the mutational bias of the malaria 
parasite. The genome of P. falciparum consists of about 82% A–T nucleotide pairs (34), 
reflecting a strong mutational bias toward A or T (25). The mutation matrix (Table S3) 
was estimated using a genome-wide collection of 1105 single-nucleotide 
polymorphisms (SNPs) in intergenic regions, culled from publicly available sequencing 
reads from P. falciparum and its sister species P. reichenowi. Methods of analysis are 
explained in the text accompanying Table S3. 
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Analysis of Evolutionary Pathways 
We used computer simulation to explore the evolutionary implications of the results in 
Fig. 1. A flow chart of the computer algorithm is provided in Fig. S1. Briefly, replicate 
evolutionary landscapes were defined by random sampling of IC50 values for each of 
the 16 possible alleles from normal distributions with the allele-specific genotypic 
means and standard deviations depicted in Fig. 1. The possible evolutionary paths 
along each landscape were then explored by randomly choosing single-step mutations, 
including possible reverse mutations, according to the mutation model in Table S3. 
Each new mutant allele was discarded if its IC50 value was smaller than that of the 
prevailing allele, and otherwise the mutant was fixed or lost according to the difference 
between the ranks of the IC50 values defining the evolutionary landscape. This 
procedure reflects the principle that the probability of fixation of a new mutation is 
proportional to its selective advantage, while the use of ranks renders the multitude of 
simulated fitness landscapes commensurate. Evolution on each simulated landscape 
was continued until either fixation of the allele with the maximum IC50 occurred, or 
else fixation of a different allele at a submaximal fitness peak took place, whose single-
mutant neighbors all had lower IC50s. 
  Simulation of 10,000 landscapes with 1000 independent excursions in each 
landscape identified 10 evolutionary pathways that were traversed at significant, 
though very uneven, frequencies. These evolutionary pathways are shown in red in Fig. 
2, where the vectors of 0's and 1's again depict the amino acid residues 51, 59, 108, and 
164. A large number of other pathways were realized, each at a negligible frequency, 
which included all pathways with mutational reversions. These rare pathways mainly 
reflected the random sampling of extreme values from the distributions in Fig. 1, 
resulting from the large number of simulated landscapes. Lozovsky et al. Page 11 
  To estimate the relative probabilities of the prominent pathways more precisely, 
we chose 100 of the landscapes at random and explored each with one million 
independent evolutionary excursions. The results confirmed the prominence of the 10 
previously mentioned pathways, and yielded the estimates of the relative probability of 
each pathway shown at the right in Fig. 2 in the column headed "Prob." Only those 
evolutionary pathways traced in red constitute the top 10 in the simulations, with the 
more likely pathways traced in thicker lines. 
  The relative frequencies of the 10 major pathways were virtually identical when 
10,000 landscapes were traversed one thousand times each, or when 100 landscapes 
were traversed one million times each. This consistency reflects the relatively small 
standard deviations among the IC50 distributions (Fig. 1). The probabilities in Fig. 2 are 
primarily determined by the differences in IC50, and are only slightly affected by the 
magnitude of the mutation bias. 
  Just three pathways in Fig. 2 account for 87.5% of those traversed at significant 
frequencies in the simulations. All three of these pathways feature S108N as the first 
step, and the two most likely include C59R as the second step. Similarly, all three of the 
most likely pathways have I164L incorporated either last or else next to last.  
   
Comparison with DHFR Polymorphisms 
The results in Fig. 2 are consistent with the combinations of amino acid replacements 
observed at significant frequencies in worldwide surveys of P. falciparum (Table 1, Refs. 
in Table S4). The common polymorphisms are indicated by the red ovals in Fig. 2, and 
they coincide with the intermediates predicted in the most likely pathways. 
  Note in Table 1 that the quadruple mutant has not yet been found at significant 
frequencies in Africa. The absence of this allele in Africa is all the more surprising in 
light of the compelling evidence that pyrimethamine resistant alleles in Africa derived Lozovsky et al. Page 12 
from those present in Southeast Asia, where the quadruple mutant is quite common 
(23). Our results may also bear on this issue. In the absence of pyrimethamine, the 
growth rates of the strains bearing 0010 (S108N), 0110 (S108N + C59R), or either of the 
triple mutants, is not manifestly impaired relative to the previous step or even the 
nonmutant allele (Fig. 3, Table S2). These results are consistent with previous inferences 
based on comparisons of the Michaelis constant (Km) and catalytic turnover rate (kcat) of 
the wildtype and mutant enzymes (35). However, when the fourth mutation is added, 
either N51I or I164L, creating the quadruple mutant, there is a strongly deleterious 
interaction between N51I and I164L, with the result that the fourth mutation decreases 
growth rate in absence of pyrimethamine by 30–40% (Fig. S2), even though it increases 
IC50 by 25–50% (Fig. 1). Hence, in the absence of compensatory mutation (see 
Discussion), the potential fitness cost of incorporating the last mutation in the pathway 
is substantial. 
 
Discussion 
Previous in vitro studies of the mutant DHFR proteins and their susceptibility to 
inhibition by pyrimethamine have identified three hypothetical pathways for the 
stepwise evolution of resistance (6). These are precisely the three most likely pathways 
identified in Fig. 2. Our data take the analysis a step farther in providing estimates of 
the relative likelihoods of the pathways. The order of amino acid replacements S108N, 
C59R, N51I, I164L is favored by a factor of about two over S108N, C59R, I164L, N51I, 
and the latter is favored by another factor of about two over S108N, N51I, C59R,  I164L. 
These three pathways together account for 87.5% of the excursions over the 
evolutionary landscape that occur with significant frequencies based on the data in Fig. 
1.  Lozovsky et al. Page 13 
Pyrimethamine acts by competing with dihydrofolate for access to the binding 
pocket of DHFR. Because endogenous DHFR activity is essential for viability, the evolution 
of resistance occurs through increased substrate specificity (36). The key kinetic parameters 
are the Michaelis constant (Km), the pyrimethamine dissociation constant (Ki), and the 
catalytic turnover rate (kcat) (6). The competitive binding dynamics are biphasic, which 
implies that the rate of product production is largely independent of catalytic capacity 
(kcat/Km) if the relative preference of the enzyme for substrate (Ki/Km) is below some 
threshold. Consistent with this picture, the pathways with the highest probabilities in Fig. 2 
all improve the substrate specificity at the expense of catalytic capacity. According to Table 
3 in Ref. (6), relative to the nonmutant DHFR, the quadruple mutant shows an approximate 
500-fold increase in Ki/Km at the expense of about a 6-fold decrease in kcat/KM. Interestingly, 
among the single mutants, S108N yields the largest increase in IC50 relative to the 
nonmutant allele, and it is clinically the most important (14, 21), even though C59R yields 
both a larger increase in both Ki/Km and kcat/Km (6). This observation implies that protein 
attributes beyond kinetic constants alone also contribute to differences in IC50. Obvious 
candidates include protein folding, stability, potential for aggregation, rate of degradation, 
and so forth, and the role of natural selection acting through such factors has been discussed 
(37). While DHFR is an established model system for the study of protein folding (38), such 
data for the pyrimethamine-resistant DHFR alleles are as yet unavailable. 
  The fitness cost of the quadruple mutation in the absence of pyrimethamine (Fig. 
3) may help explain why the quadruple mutant has not yet spread in Africa. An 
intriguing link between the evolution of drug resistance and the intensity of malaria 
transmission has been noted: Drug resistance may evolve more readily in areas of low 
transmission (7). A possible mechanism is that some drug-resistance mutants may have 
deleterious effects on fitness in the absence of the drug, which may be tolerated because 
of compensatory mutations that occur elsewhere in the genome (8). In areas of low Lozovsky et al. Page 14 
transmission, inbreeding is relatively high and genetic recombination restricted, and so 
the deleterious drug-resistance determinant and the compensatory mutations can 
remain genetically associated. In areas of high transmission, however, frequent mixed 
infectious result in genetic recombination, which breaks down the association between 
the mutant genes. 
  Consistent with the hypothesis of compensatory mutation, a copy-number 
polymorphism in the gene encoding GTP-cyclohydrolase I, the first gene in the folate 
biosynthetic pathway, has recently been shown to be associated with the DHFR 
quadruple mutant in Thailand (9). Elsewhere in the genome, a selective sweep 
associated with pyrimethamine resistance has been reported across a region of 
chromosome 13 (39). It is an interesting, testable hypothesis that this region of 
chromosome 13 may include one or more mutations that also alleviate deleterious 
fitness effects of DHFR resistance alleles. 
  While previous studies of mutationally accessible pathways to high-fitness 
sequences (29-32, 40) have explored the evolution of novel functions, pathways were 
not penalized if they simultaneously caused the organism to lose other functionality. In 
this sense, our experiment provides the first glimpse of the constraint imposed on 
evolutionary pathways by the adaptive conflict between inhibitor resistance and 
maintenance of sufficient endogenous activity. Nevertheless, levels of constraint on 
pathways in DHFR are comparable to previous work, in which constraint was a 
reflection of epistasis in a single trait, and many but not all evolutionary pathways are 
rendered inaccessible to selection. 
  Of great interest in exploring evolutionary landscapes is the possible existence of 
submaximal fitness peaks, at any of which a population may become stranded because 
every one-step mutation has a lower fitness. The DHFR landscape features one such 
submaximal peak. The sequence 1001 (N51I + I164L) has an IC50 of about 100 µg/ml, Lozovsky et al. Page 15 
and it is surrounded on the landscape by 1101 (N51I + C59R + I164L), 1011 (N51I + 
S108N + I164L), 1000 (N51I), and  0001 (I164L), which have IC50s of about 56, 57, 0.4, 
and 0.3 µg/ml, respectively (Fig. 1). Hence 1001 is accessible through either 1000 or 
0001, but neither pathway is realized frequently enough to be among the top 10 (Fig. 2), 
mainly because among the single mutants, the mutation yielding S108N (G–C to A–T) is 
strongly favored to be fixed. Interestingly, the low fitness of the quadruple mutant in 
the absence of pyrimethamine (Fig. 3) is not observed in 1001 (N51I + I164L). Evidently, 
the deleterious interaction between N51I and I164L occurs only on a background of 
C59R + S108N. 
  The observed polymorphisms in natural populations of P. falciparum in Table 1 
are consistent with the three major pathways identified in our analysis. Such agreement 
would not necessarily be expected. Drug treatment in a laboratory setting is carefully 
controlled and reproducible, whereas that in the field is variable depending on drug 
dosage, frequency, potency, pharmacokinetics, compliance, and other factors. 
Moreover, our results were obtained from studies in the E. coli system, not in P. 
falciparum itself, and some significant disparities might have been anticipated in view of 
the vast evolutionary distance between these organisms. It is therefore reassuring that 
the inferred major pathways receive additional support from the naturally occurring 
polymorphisms as well as from the kinetic studies discussed earlier. More generally, 
such support augers well for a similar use of model organisms in future studies of the 
evolution of drug resistance, not only in the malaria parasite, but also in many other 
organisms. 
 
Methods 
The sequence coding for DHFR amino acids 1–239 was isolated from P. falciparum strain K1 
by the polymerase chain reaction and cloned into the vector pET17 (Novagen) without the Lozovsky et al. Page 16 
T7 tag. The resulting plasmid was transformed into E. coli strain HMS174(DE3) (Novagen), 
and the construct confirmed by sequencing. DHFR mutants were introduced by 
QuikChange site-directed mutagenesis (Stratagene) and reintroduced into strain 
HMS174(DE3). Residues Asn51, Cys59, Ser108 and Ile164 were changed to Ile, Arg, Asn, 
and Leu, respectively, individually and in all possible combinations, using oligonucleotides 
(Operon). The mutants were all confirmed by DNA sequencing. 
  Estimates of IC50 (Table S1) were obtained as follows. Overnight cultures grown in 
rich LB medium, containing 50 ug/ml of carbamicillin to maintain the DHFR plasmid, were 
diluted and the cells allowed to grow into log phase. Aliquots of these cultures were diluted 
to approximately 10
7 cells/ml in a series of concentrations of pyrimethamine in LB 
containing 5 uM of trimethoprim, and dispensed into the wells of 96-well microtiter plates. 
The plates were incubated in the dark at 37
ºC for 19–20 hours, and the resulting cell 
concentrations estimated spectrophotometrically from the optical density at 600 nm. 
Preliminary experiments identified the interval in which the IC50 was likely to be found, 
and final estimates were based on concentrations bracketing this interval. Growth rate as a 
function of pyrimethamine concentration was estimated by polynomial regression, and the 
IC50 value estimated from this curve. To minimize the experimental error as much a 
possible, the overall IC50 for each of the 16 DHFR alleles was estimated from the IC50 
values observed in 4–8 independent biological replicates and 4 technical replicates of each 
biological replicate.  
  For the MIC assays (Table S1), bacterial strains were streaked onto fresh agar 
medium consisting of LB broth and trimethoprim plus various concentrations of 
pyrimethamine in increments of 25 µg/ml, and the plates were incubated at 37°C for 18 
hours. For each DHFR allele, the MIC was estimated with a minimum of three 
biological replicates. 
 Lozovsky et al. Page 17 
  Excursions through evolutionary landscapes were simulated by means of an 
algorithm implemented in PERL. A flow chart of the algorithm is shown in Fig. S1. 
Mean pathway probabilities and their 95% confidence intervals were estimated using 
scripts written in R (v2.2.1, The R Foundation for Statistical Computing). Ad hoc 
analysis and computer graphics were carried out in Mathematica (Wolfram Research). 
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Figure Legends 
Fig. 1. Mean IC50 values for pyrimethamine among the 16 possible combinations of mutant 
amino acid sites in DHFR. The error bars are the standard deviations of the estimated 
sampling distributions of IC50.  
 
Fig. 2. Major inferred pathways for the evolution of pyrimethamine resistance. The top 10 
pathways are shown in red along with their estimated probabilities. 
 
Fig. 3. Relative growth rates of each intermediate in the two major evolutionary pathways. 
The growth rate of each strain after each step in the pathway is measured relative to 
strain carrying the immediately preceding allele. The final steps in the pathway 0110–
1110–1111 are shown in orange, those in the pathway 0110–0111–1111 are shown in red. 
The error bars are 95% confidence intervals.  
 
Table legends 
Table 1. Common polymorphic DHFR alleles in P. falciparum 